



Blood Culture and Sensitivity Profile Study in a Tertiary Medical Hospital in Kolkata, West Bengal: 7 Years' Experience

¹Ashis K Saha, ²Kausik Muni, ³Payodhi Dhar

ABSTRACT

Aims and objectives: To identify the prevalence of bacteremia and the spectrum of antimicrobial sensitivity in our community, because it will guide the clinician to institute proper antimicrobial therapy.

Background: Bacteremia originates from either intravascular sites or extraVascular sites. In case of bloodstream infection, either Gram-positive or Gram-negative bacteria are responsible. Of these bacterial isolates, Gram-negative bacteria are responsible for higher mortality and morbidity. Since 20 to 30 years, coagulase-negative Staphylococci are responsible for most infection.

Materials and methods: In this retrospective study, blood samples were collected aseptically from 11,581 patients and were injected into the bottles containing bile-broth and brain-heart infusion broth and allowed to be incubated at 37°. Then subculture was done on blood agar, chocolate agar, as well as MacConkey agar media and was kept for 7 days or till the appearance of growth of the organism. After identification of isolates, Kirby Bauer disk diffusion test on Mueller-Hinton agar II was performed to detect antimicrobial sensitivity.

Results: Our study documented 8.58% positive cultures in the last 7 years. Gram-negative bacterial isolates were significantly higher than Gram-positive isolates (64.19% vs 34.80%, $p=0.00$). Lowest number of positivity was seen in *Morganella* (0.40%) followed by *Proteus* (0.50%) and *Enterococcus faecium* (0.90%) in ascending order. Males were significantly more culture positive than females (549/994 vs 445/994, $p=0.00$). Most common bacterial isolates were (coagulase negative Staphylococci) CoNS (239, 24.04%) followed by *Klebsiella* including ESBL (extended spectrum beta-lactamase), carbapenamase producer (234, 23.74%) and *Escherichia coli* (110, 11.06%). *E. coli* was >75% sensitive to imipenem group, polymyxin B (98.18%), colistin (96.36%), and amikacin (80.9%). Coagulase negative *Staphylococci* showed more than 60% sensitivity to levofloxacin (76.98%), amikacin (82.84%), tigecycline (87.44%), vancomycin (94.45%), teicoplanin (91.63%), linezolid (91.21%), gentamicin (76.56%), netilmicin (74.47%), and tetracycline (75.31%). *Klebsiella* (non-ESBL and carbapenamase producer) was highly sensitive to polymyxin B (93.06%), colistin (91.90%), meropenem (65.31%), and imipenem (94.73%). Extended spectrum beta-

lactamase-producing *Klebsiella* showed increased sensitivity to meropenem (89.47%), imipenem (94.73%), ertapenem (81.57%), polymyxin B, and colistin (97.36% each).

Conclusion: Positive cultures were 8.58% in the last 7 years. Gram negative bacterial isolates were significantly higher. Males were more culture positive. Most common bacterial isolates were CoNS followed by *Klebsiella* species and *E. coli*. Gram-negative bacterial isolates were highly sensitive to piperacillin, cefoperazone, imipenem, meropenem, aminoglycoside group of antibiotics, tigecycline, polymyxin B and colistin. Gram-positive bacterial isolates were sensitive to piperacillin, cefoparazone, vancomycin, teicoplanin, linezolid and clindamycin. *Salmonella typhi* were sensitive to ampicillin, cefoparazone, cefepime, azithromycin, chloramphenicol, and fluoroquinolones. *Acinetobacter* showed >50% sensitivity to cefepime and *Pseudomonas* showed >50% sensitivity to cefotaxime and levofloxacin. So to prevent resistance of bacterial isolates, a proper antibiotic guideline should be maintained.

Keywords: Blood culture and sensitivity, Coagulase negative *Staphylococcus*, *E. coli*, Gram-positive and Gram-negative bacterial isolates, *Klebsiella*, Tertiary care hospital.

How to cite this article: Saha AK, Muni K, Dhar P. Blood Culture and Sensitivity Profile Study in a Tertiary Medical Hospital in Kolkata, West Bengal: 7 Years' Experience. MGM J Med Sci 2016;3(1):18-25.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

Episodic bacterial colonization in blood circulation is called bacteremia.¹ This bloodstream infection may be life threatening in few circumstances leading to septic shock and eventually death. Bloodborne infection is a major cause of morbidity and mortality.² In 1899, Brill reported the first case of bacteremia due to bacillus pyocyaneus (which is now known as *Pseudomonas aeruginosa*). After 10 years, 40 cases were reported worldwide and 30 more cases were documented in the next 15 years.³ There are two types of bloodstream infections: first one is intravascular – it originates from cardiovascular system, e.g., infective endocarditis, mycotic aneurysm, catheter insertion. Second one is extravascular – it originates from extravascular sites, like lung, lymphatic system, kidney, bones, etc.⁴ Malaria and bloodstream infection are clinically indistinguishable when a patient comes with fever,

¹Associate Professor, ²Assistant Professor, ³Junior Resident

¹⁻³Department of General Medicine, KPC Medical College and Hospital, Jadavpur, Kolkata-700089, West Bengal

Corresponding Author: Ashis K Saha, Associate Professor Department of General Medicine, KPC Medical College and Hospital, P-5, Block-B, Lake Town, Kolkata-700089, West Bengal India, Phone: +919433006157, e-mail: asissaha2008@gmail.com

even the World Health Organization has failed to identify and distinguish these two cases.⁵⁻⁸ In case of bacterial infection, Gram-negative bacteria are responsible for more mortality than infection due to Gram-positive bacteria. Over the past 20 to 30 years, *Escherichia coli* and staphylococcal infection continue to be the most common causative organisms, but recently, bacterial spectrum has changed. Nowadays, there is substantial increase in bloodstream infection due to coagulase negative *Staphylococcus*.⁹ *Staphylococcus epidemidis* is responsible for infection in pediatric population followed by incidence of *Staphylococcus aureus* infection. There is also increasing frequency of changes in antimicrobial resistance of microbial isolates throughout the world.^{10,11} For example, there is emerging resistance to fluoroquinolones and broad spectrum cephalosporins in Enterobacteriaceae, oxacillin in Staphylococci, vancomycin in Enterococci, and penicillin in Streptococci.^{10,12} So, to prevent mortality, rapid and reliable detection of bacteria is essential worldwide and it can be accomplished by doing blood culture in proper time and in proper condition. This will guide the physicians to introduce proper antibiotic in adequate doses. In this study, our aim was (1) to identify the prevalence of microbes in our patients, (2) to study the spectrum of antimicrobial sensitivity to these microbes by performing *in vitro* culture sensitivity test, because it will guide the clinician to institute the proper antimicrobial therapy.¹³

MATERIALS AND METHODS

This was a retrospective study of 7 years period (2009 to 2015) in KPC Medical College and Hospital, Kolkata, West Bengal. This study was started only after getting permission from our local ethical committee.

Study Populations

Patients with respiratory tract infection, urinary tract infection, infective endocarditis, large abscesses in different areas of the body, osteomyelitis, ventilator-associated pneumonia, catheter-induced infection were recruited for the study.

Sample Size

A total of 11,581 blood cultures were performed, of which 994 cultures were positive.

Method of Culture

Blood samples were collected aseptically using sterile needle and syringe from the patients before antibiotic administration. But in case of patients getting antibiotics, prior to next schedule dose blood sample was collected.

In case of adult and pediatric patients, 5 and 2 ml blood was collected respectively.⁴

Processing of Specimen

Aseptically collected blood was injected into the bottles containing bile broth and brain-heart infusion broth and allowed to be incubated at 37°. Blood bottles were examined periodically at regular intervals for any evidence of bacterial growth, hemolysis, turbidity, and any gas production. Then subculture was done on blood agar, chocolate agar, as well as MacConkey agar media and was kept for 7 days or till the appearance of growth of the organism.¹⁴ Then the colonies were processed for a series of tests for identification of isolates based on motility test, Gram stain, and biochemical tests. After identifying the isolates, Kirby Bauer disk diffusion test on Mueller-Hinton agar II was performed to detect antimicrobial sensitivity according to recommendation of Clinical and Laboratory Standard Institute.¹⁵ In each culture plate, antibiotic disk (oxid) was applied and kept for 24 hours in 35°C. Antibiotic zones were measured and interpreted accordingly.

Statistical Analysis

The data were analyzed by using software Statistical Package for the Social Sciences (SPSS) version 18. A value of $p < 0.05$ was accepted as significant.

RESULTS

Total number of positive cultures was 994 out of total blood sent for culture of 11,581, percentage of positivity being 8.58%. Among the 7 years' study, in 2014 and 2015, the percentages of positive blood cultures were highest (17–16.49% respectively). Again in these 2 years, males showed significantly positive cultures as compared with females (102 *vs* 67 in 2014 and 95 *vs* 69 in 2015, $p = 0.00$). Similar result was demonstrated in 2011 (89 in males *vs* 46 in females, $p = 0.00$). Again, in total study, males were significantly positive than females (549 *vs* 445, $p = 0.00$) (Table 1).

Table 1: Year-wise male and female distribution of bacterial isolates

Years	Total cases (994)	Sex		p-value
		Males	Females	
2009	105 (10.56%)	53	52	0.89
2010	129 (12.97%)	71	58	0.10
2011	135 (13.58%)	89	46	0.00
2012	151 (15.19%)	74	77	0.72
2013	141 (14.18%)	65	76	0.19
2014	169 (17%)	102	67	0.00
2015	164 (16.49%)	95	69	0.00
		549	445	0.00

Table 2: Sex-wise distribution of bacterial isolates

Bacterial isolates	Males	Percentage	Females	Percentage	p-value
<i>Escherichia coli</i> (110) (11.06%)	54	49.09	56	50.90	0.78
Coagulase negative <i>Staphylococcus</i> (239) (24.04%)	120	43.93	119	49.79	0.92
<i>Klebsiella</i> (173) (17.40%)	105	60.69	68	39.30	0.00
<i>Klebsiella</i> (ESBL) (38) (3.82%)	25	65.57	13	34.21	0.00
<i>Klebsiella</i> (CARB) (25) (2.51%)	15	60	10	40	0.15
<i>Morganella</i> (4) (0.40%)	3	75	1	25	0.15
<i>Proteus</i> (5) (0.50%)	2	40	3	60	0.52
<i>Enterococcus faecium</i> (9) (0.90%)	6	66.66	3	33.33	0.15
<i>Staphylococcus</i> (86) (8.65%)	45	52.32	41	47.67	0.54
<i>Citrobacter</i> (22) (2.21%)	14	63.63	8	36.36	0.07
Nonfermenting Gram negative bacilli (73) (7.34%)	49	67.12	24	32.87	0.00
<i>Enterococcus</i> (12) (1.20%)	6	50	6	50	1
<i>Acinetobacter</i> (58) (5.83%)	26	44.82	32	55.17	0.26
<i>Pseudomonas</i> (75) (7.54%)	37	49.33	38	50.66	0.47
<i>Salmonella</i> (41) (4.12%)	28	68.29	13	31.70	0.00
<i>Burkholderia cepacia</i> (24) (2.41%)	14	58.33	10	41.66	0.24

ESBL: Extended spectrum beta-lactamase

In this study, percentage of positive cultures was highest in coagulase negative *Staphylococcus* (CoNS) (24.04%) cases, followed by *Klebsiella* (17.04%) and *E. coli* (11.06%), whereas lowest number of positivity was seen in *Morganella* (0.40%) followed by *Proteus* (0.50%) and *Enterococcus faecium* (0.90%) in ascending order. Again in case of culture positivity of *Klebsiella*, *Klebsiella* (extended spectrum beta-lactamase, ESBL producer), non-fermenting Gram-negative bacilli, and *Salmonella typhi* incidence of males were significant than in females (105 vs 68, 25 vs 13, 49 vs 24, and 28 vs 13 respectively, p=0.00) (Table 2). In our study, the total number of Gram-positive bacteria was 346 and Gram-negative bacteria was 644, with p-value of 0.00 (Table 3).

Escherichia coli was >75% positive to imipenem group, polymyxin B (98.18%), colistin (96.36%), amikacin (80.9%), and between 60 and 74% to other aminoglycoside group of drugs and piperacillin (69.09%). Coagulase negative *Staphylococci* showed more than 60% positivity to levofloxacin (76.98%), amikacin (82.84%), tigecycline (87.44%), vancomycin (94.45%), teicoplanin (91.63%), linezolid (91.21%), gentamicin (76.56%), netilmicin (74.47%), and tetracycline (75.31%). *Klebsiella* (non-ESBL and carbapenemase producer) was highly sensitive to polymyxin B (93.06%), colistin (91.90%), meropenem (65.31%), and imipenem (94.73%), whereas ESBL-producing *Klebsiella* showed increased sensitivity to meropenem (89.47%), imipenem (94.73%), ertapenem (81.57%), with highest positivity to polymyxin B and colistin (97.36% each). But carbapenemase-producing *Klebsiella* was 100% positive only to polymyxin B and colistin. *Staphylococcus aureus* was highly sensitive to vancomycin (96.51%), linezolid (97.67%), teicoplanin

Table 3: Total Gram-positive and negative bacteria

Gram-positive bacteria	Gram-negative bacteria	p-value
Coagulase negative <i>Staphylococcus</i> (239)	<i>E. coli</i> (110)	0.00
<i>Enterococcus faecium</i> (9)	<i>Klebsiella</i> (173)	
<i>Staphylococcus</i> (86)	<i>Klebsiella</i> (ESBL) (38)	
<i>Enterococcus</i> (12)	<i>Klebsiella</i> (CARB) (25)	
	<i>Proteus</i> (5)	
	<i>Citrobacter</i> (22)	
	Nonfermenting Gram negative bacilli (73)	
	<i>Acinetobacter</i> (58)	
	<i>Pseudomonas</i> (75)	
	<i>Salmonella</i> (41)	
	<i>Burkholderia cepacia</i> (24)	
	<i>Morganella</i> (4)	
Total = 346	Total = 648	

ESBL: Extended spectrum beta-lactamase

(89.53%), clindamycin (82.55%), tetracycline (82.55%), gentamicin (80.23%) and 100% resistant to polymyxin B and colistin. *Acinetobacter* showed high sensitivity to only polymyxin B (84.48%) and colistin (82.75%), meropenem (62.06%), and imipenem (62.06%). *Pseudomonas* bacteria showed high sensitivity to piperacillin (80%), cefoperazone (66.68%), imipenem (92%), meropenem (70%), gentamicin (78.66%), amikacin (81.33%), netilmicin and tobramycin (76% each), fluoroquinolones (ciprofloxacin 76%, levofloxacin 89.33%), polymyxin B (94.66%), and colistin (92%). Lastly, *Salmonella typhi* was highly sensitive to chloramphenicol (73.17%), ciprofloxacin (73.1%), levofloxacin (75.60%), imipenem (90.24%), ceftriaxone (32.68%), piperacillin (75.60%), and cefotaxime (73.17%) (Tables 4A to D).

Table 4A: Antibiotic sensitivity of bacterial isolates

Organism	PEN	AMOX	OX	AMC	PIP	CES	CEFU	CFT	TIC
<i>Escherichia coli</i> (110)	0	4 (3.63%)	1 (0.9%)	26 (23.63%)	76 (69.09%)	64 (58.18%)	12 (10.9%)	12 (10.9%)	3 (2.72%)
CoNS (239)	4 (1.67%)	20 (8.36%)	77 (32.21%)	111 (46.44%)	156 (65.27%)	10 (4.18%)	48 (20.08%)	4 (1.67%)	5 (2.09%)
<i>Klebsiella</i> (173)	0	5 (2.89%)	2 (1.15%)	25 (14.45%)	69 (39.88%)	57 (32.94%)	11 (6.35%)	30 (17.34%)	10 (5.78%)
<i>Klebsiella</i> (ESBL) (38)	0	0	0	0	18 (47.36%)	15 (39.47%)	0	0	0
<i>Klebsiella</i> (CARB) (25)	0	0	0	0	0	0	0	0	0
<i>Morganella</i> (4)	0	0	0	0	3 (1.2%)	1 (4%)	0	1 (4%)	0
<i>Proteus</i> (5)	0	0	0	0	2 (40%)	4 (80%)	0	0	0
<i>Enterococcus faecium</i> (9)	0	1 (11.11%)	0	2 (22.22%)	2 (22.22%)	1 (11.11%)	0	1 (11.11%)	1 (11.11%)
<i>Staphylococcus</i> (86)	6 (6.97%)	23 (26.74%)	48 (55.81%)	53 (61.62%)	57 (66.27%)	4 (4.65%)	33 (35.37%)	14 (16.27%)	1 (1.16%)
<i>Citrobacter</i> (22)	0	3 (13.63%)	1 (4.54%)	4 (18.18%)	16 (72.72%)	12 (54.54%)	3 (13.63%)	7 (31.81%)	5 (22.72%)
Nonfermenting Gram negative bacilli (73)	0	2 (2.73%)	1 (1.36%)	4 (5.47%)	62 (84.93%)	47 (64.38%)	3 (4.10%)	6 (8.219%)	7 (9.58%)
<i>Enterococcus</i> (12)	0	3 (25%)	0	8 (66.66%)	9 (75%)	1 (8.33%)	1 (8.33%)	1 (8.33%)	1 (8.33%)
<i>Acinetobacter</i> (58)	0	1 (1.72%)	0	6 (10.34%)	22 (37.93%)	16 (27.58%)	3 (5.17%)	7 (12.06%)	9 (15.51%)
<i>Pseudomonas</i> (75)	0	0	0	2 (2.66%)	60 (80%)	50 (66.66%)	0	4 (5.33%)	11 (14.66%)
<i>Salmonella</i> (41)	0	5 (12.19%)	0	24 (58.53%)	31 (75.60%)	24 (58.53%)	2 (4.87%)	30 (73.17%)	9 (21.95%)
<i>Burkholderia cepacia</i> (24)	0	1 (4.16%)	0	1 (4.16%)	20 (83.33%)	9 (37.5%)	1 (4.16%)	2 (8.33%)	0

Table 4B: Antibiotic sensitivity of bacterial isolates

Organism	CXT	CFZ	CTRX	CFP	AZ	ER	AZT	ERT	IMP	CEFO
<i>E. coli</i> (110)	46 (41.18%)	22 (20%)	26 (23.63%)	22 (20%)	5 (4.54%)	0	17 (18.70%)	83 (75.45%)	98 (89.09%)	0
CoNS (239)	52 (21.75%)	6 (2.51%)	76 (31.79%)	36 (15.06%)	52 (21.75%)	80 (33.47%)	38 (15.89%)	37 (15.48%)	104 (43.51%)	2 (0.83%)
<i>Klebsiella</i> (173)	58 (33.52%)	20 (11.56%)	31 (17.91%)	25 (14.45%)	15 (8.67%)	0	16 (9.24%)	102 (58.95%)	118 (68.20%)	2 (1.15%)
<i>Klebsiella</i> (ESBL) (38)	25 (65.78%)	0	0	0	0	0	0	31 (81.57%)	36 (94.73%)	0
<i>Klebsiella</i> (CARB) (25)	0	0	0	0	0	0	0	0	0	0
<i>Morganella</i> (4)	0	2 (50%)	1 (25%)	0	0	0	0	1 (25%)	3 (75%)	0
<i>Proteus</i> (5)	1 (20%)	0	0	0	0	0	0	4 (80%)	4 (80%)	0
<i>Enterococcus faecium</i> (9)	1 (11.11%)	1 (11.11%)	1 (11.11%)	0	1 (11.11%)	0	0	1 (11.11%)	2 (22.22%)	0
<i>Staphylococcus</i> (86)	14 (16.27%)	1 (1.16%)	55 (63.95%)	38 (44.18%)	31 (36.04%)	55 (63.95%)	26 (30.23%)	16 (18.60%)	21 (24.41%)	1 (1.16%)
<i>Citrobacter</i> (22)	5 (22.72%)	4 (18.18%)	6 (27.27%)	3 (13.63%)	2 (9.09%)	1 (4.54%)	4 (18.18%)	20 (90.90%)	21 (95.45%)	0
Nonfermenting Gram negative bacilli (73)	3 (4.10%)	7 (9.58%)	11 (15.06%)	8 (10.95%)	9 (12.32%)	1 (1.36%)	4 (5.47%)	23 (31.50%)	68 (33.15%)	1 (1.36%)
<i>Enterococcus</i> (12)	0	2 (16.66%)	2 (16.66%)	1 (8.33%)	2 (16.66%)	5 (41.66%)	4 (33.33%)	3 (25%)	9 (75%)	0
<i>Acinetobacter</i> (58)	3 (5.17%)	7 (12.06%)	10 (17.24%)	5 (8.620%)	7 (12.06%)	0	2 (3.44%)	13 (22.41%)	36 (62.06%)	1 (1.72%)
<i>Pseudomonas</i> (75)	1 (1.33%)	28 (37.33%)	3 (4%)	27 (36%)	5 (6.66%)	0	24 (32%)	8 (10.66%)	69 (92%)	25 (33.33%)
<i>Salmonella</i> (41)	3 (7.31%)	12 (29.26%)	38 (32.68%)	23 (56.09%)	26 (63.41%)	0	19 (46.34%)	13 (31.70%)	37 (90.24%)	2 (4.87%)
<i>Burkholderia cepacia</i> (24)	1 (4.16%)	3 (12.5%)	2 (8.33%)	5 (20.88%)	2 (8.33%)	0	4 (16.66%)	5 (20.88%)	16 (66.66%)	0

Table 4C: Antibiotic sensitivity of bacterial isolates

Organism	MER	GEN	TOB	NET	AMK	NLX	NF	CIP	OF	LEV
<i>E. coli</i> (110)	95 (86.36%)	76 (69.09%)	74 (67.27%)	82 (74.54%)	89 (80.90%)	0	0	40 (36.36%)	36 (32.72%)	56 (50.90%)
CoNS (239)	61 (25.52%)	183 (76.56%)	98 (41%)	178 (74.47%)	198 (82.84%)	0	10 (4.18%)	134 (56.06%)	140 (58.57%)	184 (76.98%)
<i>Klebsiella</i> (173)	113 (65.31%)	78 (45.08%)	77 (44.50%)	70 (40.46%)	88 (50.86%)	0	0	50 (28.90%)	42 (24.27%)	66 (38.15%)
<i>Klebsiella</i> (ESBL) (38)	34 (89.47%)	16 (42.10%)	17 (44.73%)	18 (47.36%)	23 (60.52%)	0	0	11 (28.94%)	9 (23.68%)	14 (36.84%)
<i>Klebsiella</i> (CARB) (25)	0	1 (4%)	1 (4%)	1 (4%)	1 (4%)	0	0	0	0	0
<i>Morganella</i> (4)	2 (50%)	2 (50%)	2 (50%)	2 (50%)	2 (50%)	0	0	3	0	3 (75%)
<i>Proteus</i> (5)	4 (80%)	2 (40%)	2 (40%)	2 (40%)	2 (40%)	0	0	0	2 (40%)	2 (40%)
<i>Enterococcus faecium</i> (9)	1 (11.11%)	1 (11.11%)	0	0	1 (11.11%)	0	0	0	0	0
<i>Staphylococcus</i> (86)	17 (19.76%)	69 (80.23%)	18 (20.93%)	61 (70.93%)	64 (74.41%)	0	0	59 (68.60%)	59 (68.60%)	64 (74.41%)
<i>Citrobacter</i> (22)	19 (86.36%)	13 (59.09%)	14 (63.63%)	13 (59.09%)	15 (68.18%)	0	0	11 (50%)	11 (50%)	18 (81.81%)
Nonfermenting Gram negative bacilli (73)	67 (91.78%)	46 (63.01%)	43 (58.90%)	46 (63.01%)	49 (67.12%)	3 (4.10%)	0	54 (73.97%)	42 (57.53%)	62 (84.93%)
<i>Enterococcus</i> (12)	2 (16.66%)	8 (66.66%)	2 (16.66%)	1 (8.33%)	2 (16.66%)	0	0	8 (66.66%)	3 (25%)	8 (66.66%)
<i>Acinetobacter</i> (58)	36 (62.06%)	21 (36.20%)	19 (32.75%)	19 (32.75%)	22 (37.93%)	0	0	23 (39.65%)	7 (12.06%)	31 (53.44%)
<i>Pseudomonas</i> (75)	70 (93.33%)	59 (78.66%)	57 (76%)	57 (76%)	61 (81.33%)	0	1 (1.33%)	57 (76%)	37 (49.33%)	67 (89.33%)
<i>Salmonella</i> (41)	28 (68.29%)	4 (9.75%)	3 (7.31%)	3 (7.31%)	3 (7.31%)	17 (41.46%)	1 (2.43%)	30 (73.17%)	22 (53.65%)	31 (75.60%)
<i>Burkholderia cepacia</i> (24)	16 (66.66%)	9 (37.5%)	7 (29.16%)	7 (29.16%)	8 (33.33%)	0	0	15 (62.5%)	3 (12.5%)	17 (70.83%)

Table 4D: Antibiotic sensitivity of bacterial isolates

Organism	COT	CHLO	NIF	TET	TIG	CLIN	VAN	TEI	LID	POL	COL
<i>E. coli</i> (110)	50 (45.45%)	55 (50%)	3 (2.72%)	38 (34.45%)	87 (79.90%)	0	0	0	0	108 (98.18%)	106 (96.36%)
CoNS (239)	116 (48.53%)	170 (71.12%)	0	180 (75.31%)	209 (87.44%)	153 (64.01%)	226 (94.45%)	219 (91.63%)	218 (91.21%)	11 (4.60%)	11 (4.60%)
<i>Klebsiella</i> (173)	62 (35.83%)	67 (38.72%)	0	73 (42.19%)	134 (77.45%)	1 (0.57%)	0	2 (1.15%)	1 (0.57%)	161 (93.06%)	159 (91.90%)
<i>Klebsiella</i> (ESBL) (38)	15 (39.47%)	21 (55.26%)	0	18 (47.36%)	32 (84.21%)	0	0	0	0	37 (97.36%)	37 (97.36%)
<i>Klebsiella</i> (CARB) (25)	1 (4%)	3 (12%)	0	10 (40%)	21 (84%)	0	0	0	0	25 (100%)	25 (100%)
<i>Morganella</i> (4)	3 (75%)	1 (25%)	0	3 (75%)	3 (75%)	0	0	0	0	1 (25%)	1 (25%)
<i>Proteus</i> (5)	0	3 (60%)	0	0	0	0	0	0	0	0	0
<i>Enterococcus faecium</i> (9)	1 (11.11%)	6 (66.66%)	0	5 (55.55%)	6 (66.66%)	0	7 (77.77%)	7 (77.77%)	7 (77.77%)	1 (11.11%)	1 (11.11%)
<i>Staphylococcus</i> (86)	54 (62.79%)	59 (68.60%)	1 (1.15%)	71 (82.55%)	60 (69.76%)	71 (82.55%)	83 (96.51%)	77 (89.53%)	84 (97.67%)	0	0
<i>Citrobacter</i> (22)	7 (31.81%)	13 (59.09%)	1 (4.54%)	12 (54.54%)	17 (77.27%)	0	0	0	0	22 (100%)	22 (100%)
Nonfermenting Gram negative bacilli (73)	55 (75.34%)	12 (16.43%)	0	24 (32.87%)	26 (35.61%)	2 (2.73%)	3 (4.10%)	2 (2.73%)	3 (4.10%)	20 (27.39%)	22 (30.13%)
<i>Enterococcus</i> (12)	2 (16.66%)	4 (33.33%)	0	5 (41.66%)	3 (25%)	1 (8.33%)	8 (66.66%)	7 (58.33%)	8 (66.66%)	3 (25%)	3 (25%)
<i>Acinetobacter</i> (58)	20 (34.48%)	14 (24.13%)	2 (3.44%)	22 (37.93%)	35 (60.34%)	0	0	0	0	49 (84.48%)	48 (82.75%)
<i>Pseudomonas</i> (75)	12 (16%)	3 (4%)	0	4 (5.33%)	6 (8%)	0	0	0	0	71 (94.66%)	69 (92%)
<i>Salmonella</i> (41)	22 (53.65%)	30 (73.17%)	0	12 (29.26%)	8 (19.51%)	1 (2.43%)	1 (2.43%)	0	1 (2.43%)	16 (39.02%)	16 (39.02%)
<i>Burkholderia cepacia</i> (24)	18 (75%)	3 (12.5%)	0	4 (16.66%)	7 (29.16%)	0	0	0	0	1 (4.16%)	1 (4.16%)

CoNS: Coagulase negative *Staphylococcus*; ESBL: Extended spectrum beta-lactamase; PEN: Penicillin; AMOX: Amoxicillin; OX: Oxacillin; AMC: Ampicillin; PIP: Piperacillin; CES: Cefoperazone + Sulbactam; CEFU: Cefuroxime; CFT: Cefotaxime; TIC: Ticarcillin; CXT: Cefoxitin; CFZ: Ceftazidime; CTRX: Ceftriaxone; CFP: Cefepime; AZ: Azithromycin; ER: Erythromycin; AZT: Aztreonam; IMP: Imipenem; CEFO: Cefoperazone; MER: Meropenem; GEN: Gentamicin; TOB: Tobramycin; NET: Netilmicin; AMK: Amikacin; NLX: Nalidixic acid; NF: Norfloxacin; CIP: Ciprofloxacin; OF: Ofloxacin; LEV: Levofloxacin; COT: Cotrimoxazole; CHLO: Chloramphenicol; NIF: Nitrofurantoin; TET: Tetracycline; TIG: Tigecycline; CLIN: Clindamycin; VAN: Vancomycin; TEI: Teicoplanin; LID: Linezolid; POL: Polymyxin; COL: Colistin

Males were significantly culture positive than females (549/994 vs 445/994). Most common bacterial isolates were CoNS followed by *Klebsiella* species and *E. coli*. Since CoNS is the most common contaminant of skin, to confirm true bacteremia, blood should be taken aseptically in two occasions from the same patient. Gram-negative bacterial isolates were highly sensitive to piperacillin, cefoperazone, imipenem, meropenem, aminoglycoside group of antibiotics, tigicycline, polymyxin B, and colistin. Gram-positive bacterial isolates were sensitive to piperacillin, cefoperazone, vancomycin, teicoplanin, linezolid, and clindamycin. *Salmonella typhi* was sensitive to ampicillin, cefoperazone, cefepime, azithromycin, chloramphenicol, and fluoroquinolone group of antibiotics. *Acinetobacter* showed >50% sensitivity to cefepime and *Pseudomonas* showed >50% sensitivity to cefotaxime and levofloxacin. To prevent progressive increase in antimicrobial resistance to antibiotics in different centers, a proper guideline should be set so that ultimate aim of recovery of the severely ill patients should be fulfilled.

ACKNOWLEDGMENT

We are thankful to all the Staff, Department of Microbiology and Medical Director of our college for helping us to collect the data.

REFERENCES

- Munford, RS. Severe sepsis and septic shock. Kasper, DL.; Braunwald, E.; Fuaci, AS.; Hauser, SL.; Longo, DL.; Jameson, JL., editors. Harrison's principles and practice of internal medicine. 17th ed. Vol. 2. New York: McGraw Hill; 2008. p. 1696-1697.
- Weinstein MP, Towns MI, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of microbiology, epidemiology and outcome of bacteremia and fungemia in adults. *Clin Infect Dis* 1997 Apr; 24(4):584-602.
- Trevino, S.; Ross, D. Bacteremia and sepsis. Mahon, CR.; Lehman, DC.; Manuselis, G. Textbook of diagnostic microbiology. 3rd ed. New Delhi: Elsevier; 2007. p. 995-1009.
- Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, Woods G, editors. Infections of blood. Koneman's color atlas and textbook of diagnostic microbiology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 97-105.
- Evans JA, Adusei A, Timmann C, May J, Mack D, Agbenyega T, Horstmann RD, Frimpong E. High mortality of infant bacteremia clinically indistinguishable from severe malaria. *QJM* 2004 Sep;97(9):591-597.
- Factor SH, Schillinger JA, Killer HD, Saha S, Begum H, Hossain A, Hossain M, Dewitt V, Hanif M, Khan N. Diagnosis and management of febrile children using the WHO/UNICEF guidelines for IMCI, Dhaka, Bangladesh. *Bull World Health Organ* 2001;79(12):1096-1105.
- Bahwere P, Levy I, Hennart P, Donnen P, Lomoyo W, Dramaix-Wilmet M, Butzler JP, De Mol P. Community acquired bacteremia among hospitalized children in rural central Africa. *Int J Infect Dis* 2001;5(4):180-188.
- Van Herp M, Praque V, Rackley E, Ford N. Mortality violence and lack of access to health care in the Democratic Republic of Congo. *Disasters* 2003 Jun;27(2):141-153.
- Moyo S, Aboud S, Kasubi M, Maselle SY. Bacteria isolated from bloodstream infections at a tertiary hospital in Dares Salaam, Tanzania. Antimicrobial resistance of isolates. *S Afr Med J* 2010 Dec 1;100(12):835-838.
- Ndugulile F, Jureen R, Harthug S, Urassa W, Langeland N. Extended spectrum β -lactamses among Gram-negative bacteria of nosocomial origin from a intensive care unit of a tertiary health facility in Tanzania. *BMC Infect Dis* 2005 Oct;5: 85-91.
- Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK, Fataki M, Msangi V, Tellevik MG, Maselle SY, et al. High rate of fatal cases of pediatric septicemia caused by Gram negative bacteria with extended spectrum betalactamses in Dar es Salaam, Tanzania. *J Clin Microbiol* 2005 Feb;43(2): 745-749.
- Shah AA, Hasan F, Ahmed S, Hameed. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilliproducing extended spectrum of beta lactamses. *Res Microbiol* 2004 Jul-Aug;155(6):409-421.
- Collee, JG.; Duguid, JP.; Fraser, AG.; Marmion, BP.; Simmion, BP.; Simmons, A., editors. Laboratory strategies in the diagnosis of infective syndromes. Mackie and MacCartney practical medical microbiology. 14th ed. New Delhi, India: Elsevier; 2006. p. 55-57.
- Cheesbrough, M. District laboratory practice in Tropical Countries. Part II. Cambridge: Cambridge University Press; 2006. p. 63.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility Testing: 16th International Supplement (CLSI document M100-S16). Wayne (PA): CLSI; 2006.
- Mehta M, Dutta P, Gupta V. Antimicrobial susceptibility pattern of blood isolates from a teaching hospital in North India. *Jpn J Infect Dis* 2005 Jun;58(3):174-176.
- Qureshi M, Aziz F. Prevalence of microbial isolates in blood culture and their antimicrobial susceptibility profile. *Biomedica* 2011 Jul-Dec;27(6):136-139.
- Devi AV, Sahoo B, Damrolien S, Praveen SH, Lungran P, Devi Ksh M. A study on the bacterial profile of bloodstream infections in Rims Hospital. *IOSR J Dental Med Sci* 2015 Jan; 1(1):18-23.
- Ireng LM, Kabego L, Kinunu FB, Itongwa M, Mitangala PN, Gala JL, Chirimwami RB. Antimicrobial resistance of bacteria isolated from patients with blood stream infections at a tertiary care hospital in the Democratic Republic of the Congo. *S Afr Med J* 2015 Sep;105(9):752-755.
- Aboud S, Sabaya S, Masangi V. Bacteria isolated from blood culture specimens at Muhimbili National Hospital in Dar es Salaam, Tanzania from 1995 – 2004. *Tanzania Med J* 2005; 20(2):22-26.
- Ahmed SH, Daef EA, Badary MS, Mahmoud MA, Abd-Elsayed AA. Nosocomial blood stream infection in intensive care units at Assiut University Hospitals Upper Egypt with special reference to extended spectrum β -lactamase producing organisms. *BMC Res Notes* 2009 May;2:76.

22. Reddy EA, Shaw AV, Crump JA. Community-acquired blood stream infections in Africa. A systemic review and meta-analysis. *Lancet Infect Dis* 2010 Jun;10(6):417-432.
23. Murdoch DR. Microbiological pattern in sepsis: What happened in last 20 years? *Int J Antimicrob Agents* 2009;34 (Suppl 4):S5-S8.
24. Jombo GT, Akpan S, Epoke J, Akaa PD, Eyong KI, Gyuse AN, Amefule EN, Uket OO. Microbial isolates from clinical specimens of blood culture and antimicrobial susceptibility profiles: Findings from an analysis of 3255 blood culture specimens at a University teaching hospitals in southern Nigeria. *Int J Biol Med Res* 2010;1(3):66-70.
25. Newton O, English M. Young infant sepsis: aetiology, antibiotic susceptibility and clinical signs. *Trop Med Hyg* 2007 Oct;101(10):959-966.
26. Warren DK, Zack JE, Elward AM, Cox MJ, Fraser VJ. Nosocomial primary blood stream infections in intensive care unit patients in a nonteaching community medical centre: a 21-month prospective study. *Clin Infect Dis* 2001 Oct;33(8):1329-1335.
27. Jombo GT, Ayilara AO, Bello K, Gadzama GB, Mbaawuaga EM. Microbial isolates from surgical sites infection at a Federal Medical Centre in North Eastern Nigeria. *Mary Slessor J Med* 2006; 6(2):59-66.
28. Zarnayeva M, Slebor E, Pechinot A, Duez JM, Bujdakova H, Labia R, Neuwirth C. Survey of Enterobacteriaceae producing extended spectrum beta-lactamase in a Slovak hospital: dominance of SIV-2a and characterization of TEM-132. *Antimicrob Agents Chemother* 2005 Jul;49(7):3066-3069.
29. Baraniak A, Flett J, Sulikowska A, Hryniewicz W, Gniadkowski M. Countrywide spread of CTX M-3 extended spectrum beta-lactamase producing microorganisms of the family Enterobacteriaceae in Poland. *Antimicrob Agents Chemother* 2002 Jan;45(1):151-159.
30. Bonnet R, Sampalo JLM, Labia R, De Champs C, Sirot D, Chanal C, Sirot J. A novel CTX-M beta-lactamases (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. *Antimicrob Agents Chemother* 2000 Jul;44(7):1936-1942.
31. Cao V, Lambert T, Nhu DQ, Loan HK, Hoang NK, Ariet G, Corvalin R. Distribution of extended spectrum beta-lactamase in clinical isolates of Enterobacteriaceae in Vietnam. *Antimicrob Agents Chemother* 2002 Dec;46(12):3739-3743.
32. Pitout JDD, Thompson KS, Hanson ND, Ehrhardt AF, McSanders ES. Beta-lactamase responsible for resistance to expanded spectrum cephalosporins in *Klebsiella pneumoniae*, *Escherichia coli* and *Proteus mirabilis* isolates recovered in South Africa. *Antimicrob Agents Chemother* 1998 Jun;42(6): 1350-1354.
33. Bell JM, Turidge JD; Sentry APAC Participants. High prevalence of oxacillin-resistant *Staphylococcus aureus* isolates from hospitalized patients in Asia Pacific and South Africa: results from SENTRY surveillance programme, 1998-1999. *Antimicrob Agents Chemother* 2002 Mar;46(3):879-881.
34. Von Eiff C, Reinert RR, Kresken M, Bravers J, Hafner D, Peters G. Nationwide German multicentre study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vivo activities of quinupristin-dalfopristin. *J Clin Microbiol* 2000 Aug;38(8):2819-2823.
35. Nko-Nai AK, Ikem IC, Aziba A, Ajayi AA, Onipede OA. Bacteriological examination of chronic osteomyelitis cases in Ile Ife, Southwestern Nigeria. *Afr J Clin Exp Microbiol* 2003; 4(2):41-51.